Navigation Links
First observation of a human HAT, key proteins in numerous pathologies
Date:2/11/2014

e and releasing them in the cytoplasm or vice-versa," explains Palacn. "We knew the structure of one of the parts. Now, for the first time, we have the low resolution of the entire complex," he says.

The study, whose first four authors include the post-doctoral researcher Albert Rosell and the PhD student Elena lvarez-Marimon at IRB Barcelona, describes the structure of the 4F2hc/LAT2 complex. "We chose this complex because it shows the highest stability among human HATs and would allow a greater chance of tackling its structure. The next step is to move onto its atomic resolution," explains Rosell. "Resolution at this level, at the highest definition, will help us to study the details of how "the machine" works and to gain a greater knowledge regarding the precise drug targets," add the scientists.

Only some HATs are associated with diseases. The 4F2hc/LAT1 and 4F2hc/xCT complexes are overexpressed in many kinds of cancer. "We have better and more detailed knowledge about the complexes and so we are providing new options by which to deal with cancer," says Manuel Palacn. The lab also focuses on aminoacidurias. Mutation in the 4F2hc/y+LAT1 complex causes lysinuric protein intolerance, a rare disease with 200 known cases. Finally, mutations in the rBAT/b(0,+)AT complex lead to cystinuria, a condition with an estimated incidence of one case per 7,000 births.

Manuel Palacn's basic research into HATs seeks to identify new therapeutic targets and to improve diagnostic tools for all conditions that involve HATs, with a special focus on aminoacidurias.

The study started as part of the European project EDICT (European Drug Initiative on Channels and Transporters), a consortium comprising 21 groups and funded by 11 million euros, which aims to increase the database of membrane protein structures. In 2008, at the beginning of the project, about 100 membrane protein structures were known. Today, this number has tripled, Palacn's group having
'/>"/>

Contact: Sònia Armengou
armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Beaumont Health System first outside of Japan to test new atrial fibrillation technology
2. CONRAD wins USAID Science and Technology Pioneers Prize for development of first vaginal gel proven to reduce HIV
3. Maternal-fetal medicine professionals identify ways to reduce first cesarean
4. A scientific first: Physicists, physicians, engineers photograph radiation beams in the human body through the Cherenkov effect
5. NCCS and Clearbridge Biomedics open the regions first circulating tumor cell center
6. Dr Steven Shoshany to Become First NYC Chiropractor to Accept Bitcoin
7. A Priceless Resolution: Take That First Step Toward Financial Security
8. Dr. Kanani Announces Complimentary Consultations for First Time Patients
9. New NuGo Stronger: First Non-GMO High Protein Bar with rBGH-Free Whey Protein for Serious Athletes
10. PCG Kids Pediatric Care Group Voted in Top 20 Finalist to Win Philly's First Business Award From Firstrust Bank
11. Sarantos Releases First Music Video - "Not Where I Wanna Be"
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First observation of a human HAT, key proteins in numerous pathologies
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... from a national survey of more than 149,000 Americans including ... that 25% of adults with disabilities, compared to 16 per ... was defined as having a Body Mass Index greater than ... limb mobility difficulties and those who had not received exercise ...
... on both mice and humans are showing why some people absorb ... if you eat a fatty meal or snack - a fried ... you absorb is strongly influenced by your genes. Experts know that ... fat diet is bad for you. But little has been discovered ...
... why surgery may trigger cognitive problems in some people ... older people develop problems with memory and other mental functions ... Cognitive Dysfunction (POCD).Often relatives will say that the person has ... was assumed, at first, that the anaesthetic was to blame. ...
... it is observed that a drug already being used ... an effective male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, ... disease, might work// as a male contraceptive because it ... fertility. They tested their theory in an animal study ...
... new study, a protein in the eye has prevented and ... this could lead to promising treatments for other// autoimmune diseases ... from the Schepens Eye Research Institute in Boston found the ... drug. The drug can then prevent the onset of and ...
... researchers suggests that nurses and junior doctors can both carry ... competence.,There's a shortage of junior doctors in the UK// and ... to take over some of their roles. Researchers in Ireland, ... nurses assess people before surgery. ,They found that ...
Cached Medicine News:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Allows for the organized storage of blocks that have been embedded using: Tissue Cassettes, Biopsy Cassettes, Mesh Cassettes, Mega Cassettes, Processing/Embedding Cassettes and Embedding Rings....
Unit System Slide Cabinet is constructed from hardwood for long lasting....
Shandon Slide File Storage System...
Shandon Microscope Slide Trays...
Medicine Products: